<DOC>
	<DOCNO>NCT00271765</DOCNO>
	<brief_summary>The primary purpose study assess safety INO-1001 subject experience heart attack treat coronary angioplasty .</brief_summary>
	<brief_title>A Study INO-1001 , Intravenous PARP ( Poly ADP Ribose Polymerase ) Inhibitor Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description>Currently , heart attack may treat clot-dissolving medicine , coronary angioplasty , combination . Unblocking blood flow heart follow coronary angioplasty cause side effect heart tissue blood vessel damage , abnormal heart rhythms death heart muscle cell . In animal study , PARP enzyme show involved damaging heart muscle sudden unblocking coronary artery . INO-1001 block PARP enzyme , may reduce heart damage human coronary artery unblocked heart attack . A total 40 patient select randomly assign either INO-1001 placebo ( sugar water ) . One dose drug give prior coronary angioplasty . Patients follow 30 day surgery . The following information gather : vital sign , symptom , physical examination , blood urine test , electrocardiogram , information medical chart . The information provide listing disclose solely comply regulatory requirement . The drug INO-1001 yet approve marketing available patient participate clinical trial chosen treatment group .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Subjects acute myocardial infarction ( define protocol ) onset within 24 hour prior randomization . Scheduled primary percutaneous coronary intervention within 3 hour presentation hospital participate study . Males nonpregnant , nonlactating female . Subjects require undergo full medical review order exclude serious medical , psychological illness prior inclusion . History hypersensitivity reaction three drug mannitol . Participation investigational study within 30 day randomization Treatment certain restrict medication within specified time prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Myocardial infarction</keyword>
	<keyword>Coronary angioplasty</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>PARP inhibition</keyword>
	<keyword>Heart Attack</keyword>
</DOC>